DBV Technologies profile in the U.S. has risen along with its stock since the French biotech listed its shares on the Nasdaq in October, said CEO Dr. Pierre-Henri Benhamou.
Five of 27 patients with an aggressive and hard-to-treat form of breast cancer responded to treatment with Merck's checkpoint inhibitor Keytruda.
Jim Cramer says Bluebird Bio's presentation at the American Society of Hematology was very impressive, but Conn's earnings report has too many questions marks.
Beta-thalassemia patients no longer require blood transfusions following a single treatment with Bluebird's LentiGlobin gene therapy.
U.S. markets teetered near the flat line in midday trading on Monday. Only the Nasdaq managed to climb over to the green on the back of biopharma stocks.
Here's what I learned about biotech and drug stocks after covering the American Society of Hematology annual meeting.
U.S. stock futures point lower as export growth in China slumps; Merck is in talks to buy Cubist; Uber is banned in New Delhi.
Sunesis' experimental leukemia drug vosaroxin underwent a miraculous transformation during a Sunday morning press briefing at the American Society of Hematology.
Celgene has worldwide clinical development and marketing rights to the two Acceleron drugs, known as luspatercept and sotatercept.
Agios and Celgene are accelerating development of AG-221 based on updated results from an early study showing strong and durable activity.
Drug maker Merck MRK is in talks to acquire the biopharmaceuticals company Cubist CBST for more than $7 billion, according to reports.
A new form of cancer immunotherapy known as CAR-T promises to radically change the way certain blood cancers are treated.
Checkpoint inhibitors can prime a patient's own immune system to kill certain types of blood cancer cells just like they do with solid tumors such as melanoma and lung cancer.
New Adcetris data are from a phase III study known AETHERA are being presented in full at the American Society of Hematology (ASH) annual meeting underway in San Francisco.
Scientists and investors are getting their first detailed look this weekend at a large study of Amgen's multiple myeloma drug Kyprolis.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV